Efficacy and safety of intermittent maintenance therapy after successful treatment of Mycobacterium avium complex lung disease-Reference-Cited by-同舟云学术

Efficacy and safety of intermittent maintenance therapy after successful treatment of Mycobacterium avium complex lung disease

Published:2019-03 Issue:3 Volume:25 Page:218-221
ISSN:1341-321X
Container-title:Journal of Infection and Chemotherapy
language:en
Short-container-title:Journal of Infection and Chemotherapy

Author:

Asakura Takanori^ORCID,Nakagawa Taku,Suzuki Shoji^ORCID,Namkoong Ho,Morimoto Kozo,Ishii Makoto,Kurashima Atsuyuki,Betsuyaku Tomoko,Ogawa Kenji,Hasegawa Naoki^ORCID

Publisher

Elsevier BV

Subject

Infectious Diseases,Pharmacology (medical),Microbiology (medical)

Reference16 articles.

1. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review;Prevots;Clin Chest Med,2015

2. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010;Marras;Emerg Infect Dis,2013

3. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan(1);Namkoong;Emerg Infect Dis,2016

4. Distribution of nontuberculous mycobacteria by multigene sequence-based typing and clinical significance of isolated strains;Jang;J Clin Microbiol,2014

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Mycobacterium avium Complex Pulmonary Disease: When Should I Treat and What Therapy Should I Start?;Clinics in Chest Medicine;2023-12

2. Pulmonary mycobacteriosis of sitatunga antelope caused by <i>M. avium</i> ssp. <i>hominissuis</i>;Annals of Agricultural and Environmental Medicine;2022-01-20

3. What are the challenges in commercial non-tuberculous mycobacteria (NTM) drug discovery and how should we move forward?;Expert Opinion on Drug Discovery;2019-09-30